top of page
developing novel adc-linker technology
araris biotech ag is pioneering the development of a novel, proprietary antibody-drug conjugate (adc)-linker technology. araris’ platform technology links highly potent cytotoxic agents to off-the-shelf antibodies, thus forming adcs.
accelerating and simplifying adc manufacturing
the use of adcs has previously presented challenges in manufacturing, stability, and bioavailability leading to toxicity, lack of efficacy, and drug resistance. araris addresses these major shortcomings, unlocking the potential to drastically simplify and accelerate adc development and manufacturing, and improve safety and tolerability in patients.
bottom of page